Exciting news for people living with idiopathic pulmonary fibrosis (IPF). Two large clinical trials TETON-1 and TETON-2 showed that an inhaled medication called treprostinil (Tyvaso) slows the loss of lung function in patient with … [Read more...]
Nerandomilast in Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis: A Promising New Therapeutic Approach
Introduction Idiopathic Pulmonary Fibrosis (IPF) is a progressive and often fatal interstitial lung disease marked by chronic fibrosis and inflammation of lung tissue. IPF remains a significant therapeutic challenge despite the availability of antifibrotic agents like pirfenidone and nintedanib. Recent attention has turned toward inflammation-modulating and immunoregulatory … [Read more...]
Pamrevlumab Ineffective in Treating IPF
In June of 2023 Fibrogen announced the results of the ZEPHYRUS-1 clinical trial of Pamrevlumab in IPF. Pamrevlumab entered phase 3 with much anticipation. Phase 2 work suggested that the molecule had a high chance of success. Unfortunately, in the phase 3 study which included 356 subjects, Pamrevlumab was not effective at preserving lung function. As a result, Fibrogen … [Read more...]
New Drugs Moving Forward for IPF
BI 1015550 The past few months have brought very exciting news for IPF patients. A novel drug being developed by Boehringer Ingelheim (BI 1015550) showed positive results in a phase 2 study. This new medication blocks the phosphodiesterase 4B receptor. Blockade of this receptor has shown promise in animal models by causing reduced inflammation and … [Read more...]
Pulmonary Fibrosis and Pulmonary Hypertension – a New Treatment Option
United Therapeutics announced positive results of their study looking at the role of Tyvaso in patients with pulmonary fibrosis and pulmonary hypertension. This is a landmark event. No study to date has shown positive results in this population. Patients with interstitial lung disease (broad category of lung disorders involving scarring of the … [Read more...]